Discovering, developing & commercializing broad-spectrum antivirals

Dedicated to preventing and treating life- threatening viral infections

Innovation to address high unmet medical needs

(NASDAQ: CMRX)
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need.

Brincidofovir Potential Against Ebola

SUPPRESS Phase 3 Trial

SUPPRESS is designed to demonstrate the efficacy and safety of brincidofovir for the prevention of CMV infection versus a placebo control, as no therapy is currently approved for the prevention of CMV in HCT recipients.